Medicare Policy Fuels Next-Gen Cancer Tech: RefleXion Wins Big in 2027

HAYWARD, Calif. – November 06, 2026 – In the complex ecosystem of healthcare technology, clinical innovation rarely survives on scientific merit alone. It requires the oxygen of favorable economic policy. For radiation oncology, a field historically squeezed by declining Medicare reimbursements, the Centers for Medicare & Medicaid Services (CMS) has just provided a massive influx of that oxygen.

With the release of the final 2027 Hospital Outpatient Prospective Payment System (OPPS) rule, CMS has fundamentally altered the financial calculus for cancer centers considering next-generation radiotherapy equipment. RefleXion Medical, a Hayward-based theranostics oncology company, emerged as a primary beneficiary of this policy shift. The agency not only maintained the lucrative New Technology designation for RefleXion’s biology-guided SCINTIX therapy for a third consecutive year but also finalized a staggering 36 percent reimbursement increase for intermediate-complexity intensity-modulated radiation therapy (IMRT) delivery.

Taking effect on January 1, 2027, these regulatory decisions highlight a broader trend defining our era: the deliberate use of federal payment structures to accelerate the adoption of autonomous, precision-engineered medical systems. By aligning financial incentives with technological breakthroughs, CMS is effectively de-risking the multi-million-dollar capital investments required to bring autonomous tumor tracking into community hospitals and academic medical centers alike.

Follow the Money: Medicare Policy as an Innovation Catalyst

To understand the impact of the 2027 OPPS rule, one must look at the shifting dynamics of hospital revenue. The new rule introduces a severe reduction in outpatient drug reimbursement for 340B hospitals—dropping from Average Sales Price (ASP) plus 6 percent to ASP minus 28 percent. To maintain budget neutrality, CMS finalized a 7.5 percent increase in payments for non-drug items and services across acute-care hospitals.

Within this reallocation, radiation oncology secured significant victories. The 36 percent rate bump over 2026 levels for intermediate-complexity IMRT delivery—a workhorse procedure in cancer centers nationwide—provides immediate financial relief to departments facing tight margins.

However, the preservation of SCINTIX therapy’s New Technology status is the true catalyst for RefleXion. This designation allows for accretive payment for novel procedures that are not yet adequately represented by existing reimbursement claims data. Reimbursed at nearly twice the rate of conventional stereotactic body radiation therapy (SBRT), SCINTIX utilizes specific G-codes (G0562 and G0563) that allow for premium payment in both hospital outpatient departments and freestanding radiation centers.

"CMS' continued recognition of SCINTIX therapy as a New Technology, together with increased IMRT reimbursement, is an important development for RefleXion and our customers," said Todd Powell, president and CEO of RefleXion. "These decisions reinforce the economic value of our next-generation X2 platform, which meets the everyday needs of radiation oncology departments with image-guided IMRT and SBRT, while also offering the advanced capabilities of SCINTIX autonomous radiotherapy."

For hospital chief financial officers, this dual-pronged reimbursement strategy removes the financial uncertainty that typically paralyzes the procurement of advanced medical devices. It provides a clear, predictable return on investment for high-cost capital equipment.

The Theranostics Leap: Autonomous Tumor Tracking

Beyond the economics, the CMS ruling validates a significant leap in how we treat mobile cancers. The RefleXion X2 platform represents a shift from anatomical targeting to biological targeting, a concept central to the growing field of theranostics.

Historically, treating tumors in the lungs or bones has been a game of anatomical prediction. Because these tumors move constantly as the patient breathes or shifts, radiation oncologists have had to rely on static imaging like CT or MRI scans to map a treatment area, often irradiating a larger margin of healthy tissue to ensure the moving tumor is hit.

SCINTIX therapy upends this paradigm by using the cancer’s own metabolic activity as a homing beacon. The system utilizes real-time positron emission tomography (PET) signals generated by a radiotracer (FDG) absorbed by the cancer cells. As the tumor moves, it continuously emits these signals. The X2 platform detects these emissions and autonomously directs the radiation beam to the exact location of the tumor in real time, responding to motion with sub-second latency.

RefleXion’s newly introduced X2 platform features a 20-fold increase in PET sensitivity over its first-generation predecessor. This massive upgrade in signal detection is designed to expand the range of tumors eligible for SCINTIX therapy, allowing clinicians to track even smaller or less metabolically active metastases. Currently, SCINTIX is cleared by the FDA for FDG-guided treatment of primary and metastatic lung and bone tumors, offering a lifeline to patients with complex, hard-to-target disease presentations.

The Dual-Revenue Gambit: Balancing Innovation with Everyday Utility

From a strategic standpoint, RefleXion’s approach to the market is a masterclass in medical device commercialization. The company recognizes that while biology-guided radiotherapy is a revolutionary capability, a hospital cannot justify a massive capital expenditure for a machine that only performs a niche subset of specialized treatments.

This is where the dual-revenue gambit comes into play. The X2 platform is not just a SCINTIX machine; it is a fully functional, highly advanced linear accelerator capable of performing conventional image-guided radiotherapy and SBRT for solid tumors located anywhere in the body.

By anchoring the high-tech, premium-reimbursed SCINTIX therapy alongside everyday workhorse IMRT procedures, RefleXion ensures that its machines will not sit idle. The 36 percent reimbursement increase for intermediate-complexity IMRT delivery acts as a financial floor for adopting hospitals. They can run routine cases through the X2 platform at a highly profitable rate, subsidizing the availability of the more advanced SCINTIX therapy for the patients who desperately need autonomous tracking.

Healthcare strategists note that this hybrid utility model is essential for penetrating a market dominated by entrenched legacy systems. It allows administrators to replace aging conventional linear accelerators with a system that handles the daily patient volume while simultaneously upgrading the institution's clinical capabilities to the cutting edge of theranostics.

Navigating the Competitive Landscape of Guided Radiotherapy

RefleXion does not operate in a vacuum. The radiation oncology sector is fiercely competitive, with established giants like Varian, Elekta, and Accuray constantly pushing the boundaries of precision tracking and adaptive therapy.

Varian’s Ethos system leverages artificial intelligence for daily adaptive therapy, adjusting treatment plans based on shifts in patient anatomy. Elekta’s Unity MR-Linac combines high-field MRI with a linear accelerator to provide high-resolution, real-time anatomical imaging during treatment. Accuray’s CyberKnife utilizes a robotic arm for highly precise, non-invasive radiosurgery that tracks respiration-induced movement.

However, RefleXion’s primary differentiator remains its reliance on biological, rather than purely anatomical, guidance. While MRI and AI-driven CT adaptations are incredibly powerful for visualizing organs and tumor boundaries, they do not inherently measure the biological activity of the cancer in real time. By utilizing PET emissions, SCINTIX therapy directly links the delivery of therapeutic radiation to the metabolic signature of the disease itself.

The 2027 OPPS final rule serves as a powerful market signal, indicating that federal payers are willing to reward this specific brand of biological innovation. As the January 2027 implementation date approaches, cancer centers across the country will be running the numbers, weighing the enhanced IMRT and SCINTIX reimbursement rates against the capital costs of the X2 platform. For many, the math will finally align, paving the way for a new standard of precision in the fight against metastatic disease.